{"schema_version":"secwatch.filing_event.v1","accession":"0001127537-25-000023","form_type":"8-K","ticker":"LUNG","cik":"0001127537","company_name":"Pulmonx Corp","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.599069+00:00","generated_at":"2026-05-23T01:57:58.953894+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Pulmonx Q1 2025 revenue $22.5M (+20% YoY); net loss $14.4M; reaffirms FY guidance","bullets":["Worldwide revenue of $22.5M, up 20% YoY (21% constant currency); U.S. $14.2M (+11%), international $8.3M (+39%).","Net loss $14.4M ($0.36 per share) vs $13.7M ($0.36) in Q1 2024; adjusted EBITDA loss $8.5M vs $8.0M.","Reaffirms FY2025 revenue guidance $96M-$98M; expects gross margin ~74% and OpEx $133M-$135M.","U.S. DOJ declined to intervene in case against Pulmonx and closed the civil investigative demand.","Amended CIBC loan to extend interest-only period through October 2027; cash & securities $88.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001127537-25-000023","json":"https://secwatch.observer/filing/0001127537-25-000023.json","markdown":"https://secwatch.observer/filing/0001127537-25-000023.md","text":"https://secwatch.observer/filing/0001127537-25-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1127537/000112753725000023/0001127537-25-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1127537/000112753725000023/lung-20250430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T01:57:58.953894+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}